The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Parkinson's disease involves the degeneration of dopaminergic neurons in the nigrostriatal tract ... of changes in the underlying neuronal pathways. These findings show that endogenous progenitor ...

Defects in a critical cellular pathway can lead to symptoms of Parkinson’s disease. Howard Hughes Medical Institute researchers have pinpointed defects in a critical cellular pathway that can lead to ...

The risk of Parkinson's disease is reduced by cigarette ... in particular those associated with the nigrostriatal dopaminergic pathway. There is now robust experimental evidence for a ...

Different models on the development of Parkinson's disease might represent a disease largely triggered by something in our environment, hinting at ways of preventing a significant number of cases.

Previous animal studies have suggested the involvement of those pathways in the neurodegeneration occurring in the nigrostriatal ... identify previously unknown disease modifiers as potential ...

especially in the nigrostriatal pathway. The main consequence on motor symptoms or disease progression might depend on the different subtypes involved in such processes. Thus, there is not enough ...